- Investopedia•4 days ago
Though the drug failed in phase 2 study, Ultragenyx has announced it plans to proceed with phase 3 studies.
- Investopedia•19 days ago
Supernus will see generic competition for its key epilepsy drug Trokendi XR in 2023, much earlier than its patent expiry in 2027.
- Investor's Business Daily•20 days ago
President Trump harped on drug prices in a tweet early Tuesday, prompting generic drugmakers Teva and Mylan to dip.
SUPN : Summary for Supernus Pharmaceuticals, Inc. - Yahoo Finance
Supernus Pharmaceuticals, Inc. (SUPN)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Bid||30.00 x 1000|
|Ask||30.85 x 500|
|Day's Range||29.57 - 31.33|
|52 Week Range||13.92 - 31.33|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||17.54|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|